1.1 Federal Acts & Agencies
Key Takeaways
- The Pure Food and Drug Act of 1906 prohibited adulterated and misbranded drugs but did not require pre-market safety or efficacy testing.
- The Federal Food, Drug, and Cosmetic Act (FDCA) of 1938 required pre-market proof of safety following the 1937 Elixir Sulfanilamide tragedy.
- The Durham-Humphrey Amendment of 1951 created the explicit statutory split between prescription (Rx Only) and over-the-counter (OTC) drugs.
- The Kefauver-Harris Amendment of 1962 mandated proof of both safety AND efficacy through clinical trials following the European thalidomide disaster.
- FDA MedWatch is a voluntary adverse event reporting system for healthcare professionals but mandatory for drug manufacturers under post-marketing surveillance rules.
Federal Acts & Agencies Governing Pharmacy Practice
Federal pharmacy jurisprudence in the United States is built upon a foundation of statutory acts enacted by Congress and administrative regulations promulgated by federal agencies. Understanding the evolution of federal drug laws is critical for navigating compliance, drug safety standards, approval pathways, and post-marketing surveillance on the Multistate Pharmacy Jurisprudence Examination (MPJE).
Historical Evolution of Federal Drug Statutes
Pure Food and Drug Act of 1906
Enacted in response to public outrage over unhygienic drug manufacturing and fraudulent nostrums, the Pure Food and Drug Act of 1906 was the nation's initial federal legislative effort to regulate drugs in interstate commerce. The 1906 Act prohibited the manufacture, sale, or transportation of adulterated or misbranded foods and drugs. However, the law suffered from profound statutory limitations:
- It did not require drug products to be proven safe or effective before being marketed to the public.
- It did not mandate full ingredient disclosure, clear warnings, or comprehensive directions for use on drug labels.
- Fraudulent therapeutic claims could only be prosecuted if the government proved the manufacturer possessed intentional fraudulent intent (Sherley Amendment of 1912).
Federal Food, Drug, and Cosmetic Act (FDCA) of 1938
The limitations of the 1906 Act resulted in tragedy in 1937, when Massengill Company distributed Elixir Sulfanilamide, an untested liquid antibiotic formulated with diethylene glycol—an industrial toxic solvent used in antifreeze. Over 100 people, primarily children, died of acute kidney failure.
In response, Congress passed the Federal Food, Drug, and Cosmetic Act (FDCA) of 1938 (21 U.S.C. § 301 et seq.). The FDCA created the modern regulatory architecture for pharmaceutical products:
- Pre-Market Safety Requirement: Required drug manufacturers to prove product safety to the Food and Drug Administration (FDA) through a New Drug Application (NDA) prior to commercial distribution.
- Expanded Definitions: Established comprehensive statutory definitions for drugs, medical devices, cosmetics, adulteration, and misbranding.
- Directions and Warnings: Mandated that drug labels bear adequate directions for use and warnings regarding potential habit-forming ingredients.
- Factory Inspections: Granted explicit statutory authority to the FDA to conduct pharmacy and manufacturing plant inspections and pursue federal court injunctions or product seizures.
Durham-Humphrey Amendment of 1951
Prior to 1951, federal law did not clearly differentiate between medications that could be safely self-administered by consumers and those requiring medical supervision. The Durham-Humphrey Amendment of 1951 (Prescription Drug Amendment) amended the FDCA by establishing two distinct statutory classes of commercial drugs:
- Prescription (Legend) Drugs: Drugs that are toxic, habit-forming, or possess potential for harm, or whose method of use requires expert medical supervision. Legend drugs must bear the federal statutory statement: "Caution: Federal law prohibits dispensing without prescription" (modernized under the Food and Drug Administration Modernization Act of 1997 to "Rx Only").
- Over-the-Counter (OTC) Drugs: Drugs that can be safely used by lay consumers without medical supervision when accompanied by adequate directions for use.
The amendment also legally authorized retail pharmacists to accept oral (telephone) prescriptions from authorized prescribers and to dispense prescription refills pursuant to prescriber authorization.
Kefauver-Harris Amendment of 1962
In the late 1950s and early 1960s, the sedative thalidomide was widely prescribed in Europe to treat morning sickness in pregnant women, resulting in thousands of infants born with severe limb deformities (phocomelia). FDA reviewer Dr. Frances Kelsey blocked U.S. approval due to inadequate safety data.
Congress responded by passing the Kefauver-Harris Amendment of 1962 (Drug Efficacy Amendment):
- Proof of Efficacy: Required manufacturers to prove that new drugs were not only safe, but also effective for their intended indications through adequate and well-controlled clinical trials prior to FDA approval.
- Retroactive Efficacy Review: Initiated the Drug Efficacy Study Implementation (DESI) program to evaluate the effectiveness of all drugs approved solely for safety between 1938 and 1962.
- Investigational New Drug (IND) Process: Standardized clinical trial procedures, requiring submission of an IND application and mandatory informed consent from human research subjects.
- Regulatory Oversight Shift: Transferred jurisdiction over prescription drug advertising from the Federal Trade Commission (FTC) to the FDA.
- Good Manufacturing Practices: Established Current Good Manufacturing Practices (CGMP) standards for drug manufacturing facilities.
FDA Approval Pathways & Special Designations
The FDA evaluates new pharmaceuticals through a structured multi-phase clinical trial and review pathway:
| Stage / Phase | Primary Target Population | Core Regulatory Focus & Purpose |
|---|---|---|
| Preclinical | Animal / In Vitro Models | Laboratory toxicity, pharmacokinetics, and biological activity evaluation. |
| Phase I | 20–100 Healthy Volunteers | Safety profile, initial human dosage ranges, metabolism, and excretion. |
| Phase II | 100–300 Patient Volunteers | Efficacy for target disease state, dose-response studies, and short-term side effects. |
| Phase III | 1,000–3,000 Patient Subjects | Multi-center randomized controlled trials confirming efficacy and long-term safety. |
| Phase IV | General Patient Population | Post-marketing surveillance monitoring rare adverse events and real-world outcomes. |
To expedite access to critical therapies, the FDA maintains four special drug designation pathways:
- Fast Track Designation: Facilitates development and expedites review of drugs treating serious conditions to fulfill unmet medical needs.
- Breakthrough Therapy Designation: Granted when preliminary clinical evidence indicates the drug may demonstrate substantial improvement over existing therapies on clinically significant endpoints.
- Accelerated Approval: Allows drug approval based on a surrogate endpoint or intermediate clinical endpoint reasonably likely to predict clinical benefit.
- Priority Review: Commits FDA resources to review an NDA within 6 months rather than the standard 10-month timeline.
Post-Marketing Surveillance & FDA MedWatch
The FDA MedWatch program is the federal voluntary adverse event reporting system for healthcare professionals (pharmacists, physicians, nurses) and consumers. MedWatch allows voluntary submission of reports regarding serious adverse events, product quality defects, therapeutic failures, and medication errors involving human drugs, biologics, medical devices, dietary supplements, and cosmetics.
- Voluntary vs. Mandatory: MedWatch reporting is strictly voluntary for retail and hospital pharmacists. However, pharmaceutical manufacturers face statutory post-marketing obligations to report serious, unexpected adverse events to the FDA within 15 calendar days.
- Enforcement Powers: When violative drugs pose public health risks, the FDA employs statutory enforcement tools including administrative warning letters, court-sanctioned product seizures, judicial injunctions prohibiting distribution, and criminal prosecution through the Department of Justice.
Which federal legislation was enacted directly in response to the 1937 Elixir Sulfanilamide tragedy, establishing the requirement that manufacturers prove drug safety prior to marketing?
A pharmaceutical manufacturer seeks expedited FDA development and review for a novel oncology agent based on preliminary clinical evidence demonstrating a substantial improvement over existing therapies on a clinically significant endpoint. Which official FDA designation applies?
Which statement accurately describes the MedWatch reporting system administered by the FDA?